Analysts have had to throw out their assumptions for the biopharma industry’s recovery heading into the first quarter ...

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.

Shares of CarMax sank Thursday after the used-car dealer reported fiscal-fourth-quarter earnings that missed expectations and ...

We believe the tariffs as proposed will raise the cost of both importing and manufacturing vehicles in the U.S. by at least a ...

Q3 2025 Earnings Call Transcript April 8, 2025 Operator: Greetings. Welcome to the Aehr Test Systems Fiscal 2025 Third ...

For investors looking for opportunities in fintech, SoFi presents an interesting case. Here's where analysts think the stock ...

In a report released today, Louie DiPalma from William Blair maintained a Hold rating on ViaSat (VSAT – Research Report). The company’s shares ...

In a report released today, Andy Hsieh from William Blair maintained a Buy rating on Skye Bioscience (SKYE – Research Report). The company’s ...

William Blair Institutional Intl Fund earns a Below Average Process Pillar rating. The process is strengthened by the stability of the management team. Specifically, the fund has not seen a ...